Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.
The future of drug discovery has arrived
Reducing development time, cost & risk

Investor Presentation | March 2014
Disclaimer
When used anywhere in this presentation, whether oral or written, the words expects,
believes, anticipates, est...
Critical Outcome Technologies Inc.
 A bioinformatics
and accelerated
drug discovery
company
 Listed on the TSX-V
under t...
Investment highlights

1
2

Potential cancer breakthrough drug
candidate is nearly Phase 1 ready

3

TSXV: COT

We reduce ...
Conventional drug development
is a long & expensive process
characterized by a high risk
of failure

TSXV: COT

11 – 15
ye...
What we do

 Reduce drug discovery, optimization & lead
selection by 1.5 to 3 yrs.
 Saving significant $$$
 Increasing ...
How we do it – CHEMSAS®

Proprietary,
artificial intelligence
based drug
discovery platform
technology

TSXV: COT

7
Advantages of CHEMSAS®

Computational
replication of
traditional
‘wet lab’ drug
discovery process

TSXV: COT

Failed attem...
Potential cancer breakthrough

Our lead compound,
COTI-2, is effective
against cancers with
mutations of the p53
gene

TSX...
Why COTI-2 is exciting
 > 50% of all human cancers have a p53 mutation
(eg. ~ 95% of ovarian cancers)

 Mechanism of act...
COTI-2 is (nearly) Phase 1 ready
 In final 2-species toxicity studies – completion in first
half of 2014
 FDA IND filing...
COTI-2 = significant revenue potential
 Top 5 2012 Phase 1/2 oncology licensing deals
disclosed (1):
 Upfront payments o...
Other revenue opportunities
 Robust internal pipeline of compounds
- AML, colorectal cancer, small cell lung cancer libra...
Looking ahead
Other CHEMSAS® applications:
 CHEMFirm – Small molecule
profiling & investment due
diligence tool

 Drug l...
Project ROSALIND
 Programmable computer
simulation of human cancer
cell signaling
 Better personalized
treatment decisio...
Summary

1
2

Potential cancer breakthrough drug
candidate is nearly Phase 1 ready

3

TSXV: COT

We reduce the time, cost...
The future of drug discovery has arrived
Reducing development time, cost & risk

Dr. Wayne Danter
President & CEO
Tel: (51...
Upcoming SlideShare
Loading in …5
×

Critical Outcome Investor Presentation - March 2014

1,124 views

Published on

Published in: Investor Relations
  • Be the first to comment

Critical Outcome Investor Presentation - March 2014

  1. 1. The future of drug discovery has arrived Reducing development time, cost & risk Investor Presentation | March 2014
  2. 2. Disclaimer When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forwardlooking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI). COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission. All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation. TSXV: COT 2
  3. 3. Critical Outcome Technologies Inc.  A bioinformatics and accelerated drug discovery company  Listed on the TSX-V under the symbol COT since 2006 TSXV: COT 3
  4. 4. Investment highlights 1 2 Potential cancer breakthrough drug candidate is nearly Phase 1 ready 3 TSXV: COT We reduce the time, cost & risk of bringing new drugs to market We have many more revenue opportunities in our pipeline 4
  5. 5. Conventional drug development is a long & expensive process characterized by a high risk of failure TSXV: COT 11 – 15 years $1 billion or more 1 FDA approval 5
  6. 6. What we do  Reduce drug discovery, optimization & lead selection by 1.5 to 3 yrs.  Saving significant $$$  Increasing revenue period under patent protection TSXV: COT 6
  7. 7. How we do it – CHEMSAS® Proprietary, artificial intelligence based drug discovery platform technology TSXV: COT 7
  8. 8. Advantages of CHEMSAS® Computational replication of traditional ‘wet lab’ drug discovery process TSXV: COT Failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’ Higher probability of clinical & commercial success 8
  9. 9. Potential cancer breakthrough Our lead compound, COTI-2, is effective against cancers with mutations of the p53 gene TSXV: COT 9
  10. 10. Why COTI-2 is exciting  > 50% of all human cancers have a p53 mutation (eg. ~ 95% of ovarian cancers)  Mechanism of action confirmed by thought leader Dr. Gordon Mills at MD Anderson Cancer Center (June 2013)  Novel, first-in-class  Strong IP protection in place TSXV: COT 10
  11. 11. COTI-2 is (nearly) Phase 1 ready  In final 2-species toxicity studies – completion in first half of 2014  FDA IND filing expected in second half of 2014 (leading to Phase 1 clinical trial)  Pursuing orphan drug and/or breakthrough therapy status  Signed an LOI with a strategic partner, Portage Biotech Inc., for clinical development TSXV: COT 11
  12. 12. COTI-2 = significant revenue potential  Top 5 2012 Phase 1/2 oncology licensing deals disclosed (1):  Upfront payments of approx. $25-$92 million  Milestone payments between $550-$1,100 million  Royalties on net sales  1st half of 2013 (2) – 16 Phase 1 licensing deals with 6 in cancer – avg. upfront $30m TSXV: COT (1) (2) Medius Associates Thomson Reuters 12
  13. 13. Other revenue opportunities  Robust internal pipeline of compounds - AML, colorectal cancer, small cell lung cancer library, MS, etc.  3 existing R&D collaborations expected to bring in milestone payments beginning late 2014 / 2015 - Western University - Delmar Chemicals - Major Pharma Co. TSXV: COT 13
  14. 14. Looking ahead Other CHEMSAS® applications:  CHEMFirm – Small molecule profiling & investment due diligence tool  Drug library profiling – Based on customer identified criteria  Drug repurposing – Finding new purposes for drugs coming off patent TSXV: COT 14
  15. 15. Project ROSALIND  Programmable computer simulation of human cancer cell signaling  Better personalized treatment decisions based on genetic profile of one’s cancer  Personalized cancer gene profiling projected to be * ~ $35B market by 2018 TSXV: COT * Markets and Markets (2013) 15
  16. 16. Summary 1 2 Potential cancer breakthrough drug candidate is nearly Phase 1 ready 3 TSXV: COT We reduce the time, cost & risk of bringing new drugs to market We have many more revenue opportunities in our pipeline 16
  17. 17. The future of drug discovery has arrived Reducing development time, cost & risk Dr. Wayne Danter President & CEO Tel: (519) 858-5157 wdanter@criticaloutcome.com www.criticaloutcome.com www.facebook.com/criticaloutcome twitter.com/criticaloutcome www.slideshare.net/criticaloutcome

×